Please assess the completion status of the following clinical trial:

Trial Title: Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients 65 years and older.~* Patients who have dementia and a history of acute agitation.~* History of agitation that requires intervention or impairs social or daily activities~* Patients who meet International Psychogeriatric Association (IPA) diagnostic criterion for agitation.~* Patients with a total score of ≥ 8 on the Pittsburgh Agitation Scale (PAS).~* Patients who have a score of ≥ 2 on at least 1 of the 4 items on the Pittsburgh Agitation Scale (PAS).~* Patients who read, understand and provide written informed consent, or who have a Legally Authorized Representative (LAR).~* Patients who are in good general health.~Exclusion Criteria:~* For Part B: Patients with dementia associated with Parkinson's disease and/or Lewy Body Disease, if etiology of dementia is known.~* Patients with agitation caused by acute intoxication.~* Patients treated within 4 hours prior to study drug administration with benzodiazepines, other sedatives, hypnotics or oral or short-acting intramuscular antipsychotics must be excluded.~* Treatment with alpha-1 noradrenergic blockers, alpha adrenergic antagonists within 8 hours prior to dosing.~* No new chronic medications initiated in the past 14 days prior to screening excluding over-the-counter products taken sporadically.~* Patients at significant risk of harm to themselves or others~* Patients considered medically unstable or in recovery~* Patients with history of clinically significant syncope or syncopal attacks, orthostatic hypotension within the past 2 years, current evidence of hypovolemia, orthostatic hypotension.~* Cohort 3 only: Patients who are taking nitrates or beta blockers shall be excluded. Any other anti-hypertensives should be maintained in the course of the study.~* Patients who have received an investigational drug within 30 days prior to the current agitation episode must be excluded.~* Patients experiencing clinically significant pain, per Investigator.~* Cohort 3 only: Patients who are a high fall risk assessed via the Johns Hopkins Fall Risk Assessment (total score \>13) or during the 1-week safety observation period~* Pregnancy

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1- 30 Micrograms (Type: ACTIVE_COMPARATOR): Cohort 1 consists of 10 patients out of whom 8 patients receive 30 Micrograms film and the remaining 2 patients receive a placebo
- Cohort 2- 60 Micrograms (Type: ACTIVE_COMPARATOR): Cohort 2 consists of 10 patients out of whom 8 patients receive 60 Micrograms film and the remaining 2 patients receive a placebo.~Additional 20 subjects receive 60 Micrograms or placebo.
- Cohort 3- 90 Micrograms (Type: ACTIVE_COMPARATOR): Cohort 3 consists of 10 patients out of whom 8 patients receive 90 Micrograms film and the remaining 2 patients receive a placebo
- Part B Cohort (Type: ACTIVE_COMPARATOR): Part B cohort consists 46 subjects receiving 40 Micrograms or placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).